Duncan Park Holdings Corporation

0.005

Canada & Ontario Toronto

77 King Street West, Suite 3000

www.duncanpark.com

Looking to explore investment opportunities with DPH?

Contact DPH >

Looking to explore investment opportunities with DPH?

Contact DPH >

Is this your business?
Customize your listing.

CLAIM THIS LISTING

Is this your business?
Customize your listing.

Company Press Releases

Duncan Park Announces Closing of Private Placement

TORONTO, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Duncan Park Holdings Corporation ("Duncan Park" or the "Company") (TSXV: DPH) announced today the closing of its previously announced private placement ("Private Placement") of $250,000 of convertible debentures ("Debentures"). The Debentures are convertible, at the election of the holder, into units of the Corporation ("Units"). The principal amount of the Debentures are convertible at a price of $0.05 per Unit prior to completion of the previously announced proposed consolidation ("Consolid...

Duncan Park Announces Private Placement, Shares for Debt Transactions and Other Proposed Corporate Measures

TORONTO, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Duncan Park Holdings Corporation ("Duncan Park" or the "Company") (TSXV: DPH) announced today its intention to undertake a series of transactions and other corporate measures in an effort to rationalize its capital and debt structure in an attempt to better position the Company for future opportunities. Subject to TSX Venture Exchange ("TSXV") and shareholder approval, as required, the Company proposes to undertake a private placement of $250,000 of convertible debentures ("Debentures") and satisfy the paym...

Veterinary Group Dechra - 2018 Interim Results

LONDON, February 26, 2018 /PRNewswire/ -- Dechra Pharmaceuticals PLC, LSE: Main Market: symbol DPH) today releases its Half-Yearly Financial Report 2018 for the six months ended 31 December 2017 (the Period). Ian Page, Chief Executive Officer at Dechra commented:   "Dechra has performed well in the Period with solid revenue growth in EU pharmaceuticals and strong revenue growth in NA Pharmaceuticals from the existing business. This has been delivered through the consistent application of our successful strategy, converting pipeline opportunities, leveraging our strong portfolio...

See All >

Company News

See All >

NEWSLETTER